Growth is driven by rising COPD cases due to smoking and pollution, and enhanced therapeutic options like bronchodilators and biologics. Significant investments are improving diagnosis and treatment.
Wakefield Express on MSN
COPD clinical trial: Mid Yorkshire Teaching NHS Trust recruits first patient to new COPD clinical trial
Mid Yorkshire Teaching NHS Trust has become the first site in Europe to recruit a patient to a major international clinical ...
Temple Health leads research showing how women and non-smokers face rising risks, and how new treatments are changing the ...
Chronic obstructive pulmonary disease is a condition caused by damage to the lungs that results in breathing difficulties.
Use of a COPD care pathway heightened the odds for a pulmonary rehabilitation referral and home discharge in hospitalized ...
Chronic Obstructive Pulmonary Disease, or COPD, is a progressive lung condition that affects millions of people in the United ...
Pollution-related illnesses surge, with treatment costs rising 11%, particularly affecting children, warns a Policybazaar report.
Medication treatment for COPD usually involves inhaled medications, such as beta agonists like albuterol or long-acting forms ...
Chronic obstructive pulmonary disease (COPD) affects approximately 29 million people in the U.S. and is the fourth leading ...
Anyone who breathes can develop COPD. The world is at risk, and chronic respiratory diseases must be treated as both a global ...
Medication treatment for COPD usually involves inhaled medications, such as beta agonists like albuterol or long-acting forms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback